The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A 5-year follow-up of ruxolitinib plus azacitidine in MDS/MPN overlap syndromes and CMML
Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the five-year follow-up results of a Phase II clinical trial (NCT01787487) of ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes (MDS/MPNs) or chronic myelomonocytic leukemia (CMML). In this cohort of patients, durable disease responses were seen with RUX-AZA, which led to improved disease outcomes. Dr Arora highlights that patients with high-risk disease highly benefited from this combination in the front-line setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
